Metastatic RCC risk score for VEGF/IO systemic therapy framing.
Calculated Interpretation
Favorable Risk
0 /6
No IMDC adverse factors.
Guidelines & Evidence
Clinical Details
Section 1
When to Use
Primary Use
Metastatic RCC risk score for VEGF/IO systemic therapy framing.
Section 2
Formula & Logic
Clinical Inputs
KPS < 80%
Binary clinical feature
Diagnosis to treatment < 1 year
Binary clinical feature
Hemoglobin below LLN
Binary clinical feature
Corrected calcium above ULN
Binary clinical feature
Neutrophils above ULN
Binary clinical feature
Platelets above ULN
Binary clinical feature
Section 3
Pearls/Pitfalls
Result Bands
Section 4
Next Steps
Suggested Next Steps
01
Interpret the result in the full disease-specific clinical context.
02
Correlate with pathology, imaging, performance status, and multidisciplinary guidance.
Section 5
Evidence Appraisal
Evidence Base
Metastatic RCC risk score for VEGF/IO systemic therapy framing.
OpiCalc Medical Oncology Module • Genitourinary Cancers. 2026;Logic implemented from widely used contemporary oncology classification, prognostic, and response-assessment frameworks.
Section 6
Literature
Context
IMDC (Heng) Criteria is included in the oncology module as a structured decision-support tool for genitourinary cancers workflows.
